Sally Ride and Pancreatic Cancer: A Pioneer's Private Battle

What was announced, and what was not

Sally Ride, the first American woman in space, died on Monday, July 23, 2012, at her home in La Jolla, California. She was 61.

The BBC reported the announcement from her foundation, Sally Ride Science: she died 17 months after being diagnosed with pancreatic cancer. President Barack Obama said he was "deeply saddened," calling her "a national hero and a powerful role model."

That was the whole of the public medical disclosure. She had kept her illness and her treatment private while she was alive. This article respects that and adds nothing about her care.

What is worth setting out is the organ itself. Most people could not point to the pancreas on a diagram, or say what it does. Knowing that makes the rest of this disease make sense.

What the pancreas is for

The pancreas sits deep in the upper abdomen, behind the stomach, tucked against the spine. That location is why it is so hard to examine and so hard to image clearly.

It does two unrelated jobs. The exocrine part is most of its mass. It makes enzymes that break down fat, protein, and starch, and pipes them into the small intestine through ducts. The endocrine part is a set of small cell clusters called islets. They make hormones, including insulin, and release them straight into the blood.

The National Cancer Institute divides the organ by region as well: the head, the body, the tail, and the uncinate process. Which region a tumor sits in changes the surgery entirely.

That anatomy explains the symptoms. A tumor in the head of the pancreas can squeeze the bile duct running past it. Bile backs up, and the skin and eyes turn yellow. That is why painless jaundice is such a characteristic first sign.

When to get checked

NCI states there are not many noticeable symptoms in the early stages. As the cancer grows, it lists:

• Jaundice, meaning yellowing of the skin or eyes.
• Light-colored stools or dark urine.
• Pain in the upper or middle abdomen and in the back.
• Weight loss for no known reason.
• Loss of appetite.
• Fatigue.

Thresholds that make that list usable:

• Yellow eyes or skin in an adult, without fever, needs medical attention within days. It is not a wait-and-see finding.
• Pale stools with dark urine, lasting beyond a few days.
• Upper abdominal pain that goes through to the back, is worse lying flat, and eases on leaning forward, for more than two weeks.
• Weight loss you did not intend, over one to two months, especially with appetite loss.

There is no screening program for people at average risk. NCI lists the risk factors as a family history of pancreatic cancer, cigarette smoking, obesity, chronic pancreatitis, and certain genetic conditions, including those linked to BRCA1, BRCA2, PALB2, and ATM. Two or more close relatives with the disease is a reason to ask about genetic counseling.

The word that decides the plan: resectable

Most cancers are staged first and treated second. Pancreatic cancer works differently. NCI states that clinical staging is guided by resectability, which is strongly influenced by surgical judgment.

NCI sets out the four categories used:

• Resectable: tumors without involvement of blood vessels.
• Borderline resectable: tumors involving vessels or local structures, or otherwise at high risk that surgery would leave cancer behind.
• Locally advanced: tumors whose local invasion, mostly of blood vessels, rules out surgery.
• Metastatic: cancer that has spread beyond the pancreas to other organs.

The pancreas sits among major arteries and veins. Whether a tumor has grown around one of them, rather than how big it is, often decides whether surgery is possible.

The formal TNM system runs alongside this. NCI's tables put a tumor of 2 cm or less at T1, with subdivisions at half a centimeter and one centimeter. That shows how small these tumors are while still counted as early.

What the operations actually remove

When surgery is possible, it is major. NCI describes three procedures.

The Whipple procedure removes the head of the pancreas, the gallbladder, part of the stomach, part of the small intestine, and the bile duct. Enough pancreas is left to keep making digestive juices and insulin.

A total pancreatectomy removes the whole pancreas, part of the stomach, part of the small intestine, the common bile duct, the gallbladder, the spleen, and nearby lymph nodes.

A distal pancreatectomy removes the body and tail of the pancreas, and sometimes the spleen.

When the cancer cannot be removed, NCI lists palliative operations aimed at symptoms. A biliary bypass reroutes bile around a blockage. An endoscopic stent drains a blocked bile duct. A gastric bypass connects the stomach directly to the small intestine when a tumor blocks food leaving the stomach.

NCI also notes that people with pancreatic cancer have special nutritional needs. There are treatments aimed at the pain this cancer causes. Radiation, chemotherapy, chemoradiation, and targeted therapy round out the options.

What the numbers say about groups

These are population figures. They do not describe any individual, and they were never designed to.

The American Cancer Society projects 67,530 new pancreatic cancers in the United States in 2026 and 52,740 deaths, and SEER republishes those projections. That is roughly 8.4% of all cancer deaths. Five-year relative survival across all stages is 13.7% for people diagnosed between 2016 and 2022. The disease is diagnosed most often between the ages of 65 and 74.

Stage explains the shape of the numbers. For that same 2016 to 2022 group, SEER records five-year relative survival of 43.6% for localized disease, 17.0% for regional disease, and 3.4% once the cancer has reached distant organs. Only about 15% of cases are found while still localized. Roughly 51% are distant at diagnosis.

NCI's guidance for clinicians states that exocrine pancreatic cancer is rarely curable, with an overall survival rate below 6%. Truly localized disease is less than 20% of cases. NCI notes that patients at any stage are candidates for clinical trials, because standard chemotherapy, radiation, and surgery work poorly.

What this story is actually for

Ride spent her later career pulling young people, especially girls, toward science. Her foundation still does.

The useful thing to take from her death is not a statistic about her. It is that the pancreas is a real organ doing two jobs, that a tumor in it announces itself late and vaguely, and that yellow eyes with no fever is one of the few early signs that is genuinely hard to explain away.

That fact is worth more than any number on this page.

Sources

• NCI: Pancreatic Cancer Treatment (PDQ) — Health Professional Version
• NCI: Pancreatic Cancer Treatment (PDQ) — Patient Version
• SEER Cancer Stat Facts: Pancreatic Cancer
• BBC News: Sally Ride, the first US woman in space, dies aged 61